291 related articles for article (PubMed ID: 21623854)
1. Different relationships between the first 2 years on growth hormone treatment and the d3-growth hormone receptor polymorphism in short small-for-gestational-age (SGA) children.
Dörr HG; Bettendorf M; Hauffa BP; Mehls O; Rohrer T; Stahnke N; Pfäffle R; Ranke MB;
Clin Endocrinol (Oxf); 2011 Nov; 75(5):656-60. PubMed ID: 21623854
[TBL] [Abstract][Full Text] [Related]
2. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism.
Tauber M; Ester W; Auriol F; Molinas C; Fauvel J; Caliebe J; Nugent T; Fryklund L; Ranke MB; Savage MO; Clark AJ; Johnston LB; Hokken-Koelega AC;
Clin Endocrinol (Oxf); 2007 Sep; 67(3):457-61. PubMed ID: 17555507
[TBL] [Abstract][Full Text] [Related]
3. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
Carrascosa A; Audí L; Fernández-Cancio M; Esteban C; Andaluz P; Vilaró E; Clemente M; Yeste D; Albisu MA; Gussinyé M
J Clin Endocrinol Metab; 2008 Mar; 93(3):764-70. PubMed ID: 18160465
[TBL] [Abstract][Full Text] [Related]
4. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
Carrascosa A; Audí L; Esteban C; Fernández-Cancio M; Andaluz P; Gussinyé M; Clemente M; Yeste D; Albisu MA
J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340
[TBL] [Abstract][Full Text] [Related]
6. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.
Audí L; Carrascosa A; Esteban C; Fernández-Cancio M; Andaluz P; Yeste D; Espadero R; Granada ML; Wollmann H; Fryklund L;
J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665
[TBL] [Abstract][Full Text] [Related]
7. Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA.
Audí L; Esteban C; Carrascosa A; Espadero R; Pérez-Arroyo A; Arjona R; Clemente M; Wollmann H; Fryklund L; Parodi LA;
J Clin Endocrinol Metab; 2006 Dec; 91(12):5038-43. PubMed ID: 17003087
[TBL] [Abstract][Full Text] [Related]
8. GH receptor d3 polymorphism in Dutch patients with MPHD and IGHD born small or appropriate for gestational age.
de Graaff LC; Meyer S; Els C; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Jun; 68(6):930-4. PubMed ID: 18031312
[TBL] [Abstract][Full Text] [Related]
9. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome.
Binder G; Trebar B; Baur F; Schweizer R; Ranke MB
Clin Endocrinol (Oxf); 2008 Apr; 68(4):567-72. PubMed ID: 17973940
[TBL] [Abstract][Full Text] [Related]
10. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients.
Carrascosa A; Esteban C; Espadero R; Fernández-Cancio M; Andaluz P; Clemente M; Audí L; Wollmann H; Fryklund L; Parodi L;
J Clin Endocrinol Metab; 2006 Sep; 91(9):3281-6. PubMed ID: 16804042
[TBL] [Abstract][Full Text] [Related]
11. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
[TBL] [Abstract][Full Text] [Related]
12. The growth hormone receptor exon 3-deleted/full-length polymorphism and response to growth hormone therapy in prepubertal idiopathic short children.
Hellgren G; Glad CA; Jonsson B; Johannsson G; Albertsson-Wikland K
Growth Horm IGF Res; 2015 Jun; 25(3):127-35. PubMed ID: 25742716
[TBL] [Abstract][Full Text] [Related]
13. The exon3-deleted growth hormone receptor gene polymorphism (d3-GHR) is associated with insulin and spontaneous growth in short SGA children (NESGAS).
Wegmann MG; Thankamony A; Roche E; Hoey H; Kirk J; Shaikh G; Ivarsson SA; Söder O; Dunger DB; Juul A; Jensen RB
Growth Horm IGF Res; 2017 Aug; 35():45-51. PubMed ID: 28719834
[TBL] [Abstract][Full Text] [Related]
14. Subclassification of small for gestational age children with persistent short stature: growth patterns and response to GH treatment.
Ester W; Bannink E; van Dijk M; Willemsen R; van der Kaay D; de Ridder M; Hokken-Koelega A
Horm Res; 2008; 69(2):89-98. PubMed ID: 18059089
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
16. The impact of the d3-growth hormone receptor (d3-GHR) polymorphism on the therapeutic effect of growth hormone replacement in children with idiopathic growth hormone deficiency in Poland.
Szmit-Domagalska J; Petriczko E; Drozdzynska M; Adler G; Horodnicka-Jozwa A; Ciechanowicz A; Walczak M
Neuro Endocrinol Lett; 2016 Sep; 37(4):282-288. PubMed ID: 27857044
[TBL] [Abstract][Full Text] [Related]
17. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
18. Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature.
Toyoshima MT; Castroneves LA; Costalonga EF; Mendonca BB; Arnhold IJ; Jorge AA
Clin Endocrinol (Oxf); 2007 Oct; 67(4):500-4. PubMed ID: 17555512
[TBL] [Abstract][Full Text] [Related]
19. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor.
Blum WF; Machinis K; Shavrikova EP; Keller A; Stobbe H; Pfaeffle RW; Amselem S
J Clin Endocrinol Metab; 2006 Oct; 91(10):4171-4. PubMed ID: 16868057
[TBL] [Abstract][Full Text] [Related]
20. The presence of the d3-growth hormone receptor polymorphism is negatively associated with fetal growth but positively associated with postnatal growth in healthy subjects.
Jensen RB; Vielwerth S; Larsen T; Greisen G; Leffers H; Juul A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2758-63. PubMed ID: 17426087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
